Celgene Corp. and Bristol-Myers Squibb Co. will have to pay $2.2 billion if either of the drugmakers walks away from their $74 billion merger, according to a regulatory filing.
Locus Biosciences inked a collaboration and license deal with J&J’s Janssen Pharmaceutical to develop precision antibacterial therapies based on CRISPR-Cas3-enhanced bacteriophage.
Bristol-Myers Squibb Co. will buy Celgene Corp. for about $74 billion, creating one of the largest pharmaceutical companies and combining two significant cancer medicine businesses.
Boston Scientific exercised the company’s option to buy the remaining shares of Santa Rosa, Calif.-based Millipede for $325 million.
Xynomic Pharmaceuticals, a pharma company with roots in both the U.S. and China, forged a deal worth up to $800 million to acquire a Phase II-ready cancer treatment from Germany-based Boehringer Ingelheim.
GlaxoSmithKline plans to split into two businesses – one for Rx drugs and vaccines, and the other for OTC products – after forming a new joint venture with Pfizer’s consumer health division.
Merck & Co. is paying about $2.4 billion to acquire all outstanding shares of Antelliq Group, and is also assuming the digital technology company’s debt of $1.3 billion.
Shares of Advaxis plunged more than 28 percent in premarket trading after the company quietly disclosed that Amgen terminated their collaboration on an immuno-oncology program.
The Delaware Supreme Court said in a court filing that Germany’s Fresenius SE properly terminated the company’s merger agreement with Akorn Inc., sending shares of the U.S generic drugmaker down more than 30 percent.
Akorn Inc. said the company’s chief executive officer would retire following the drugmaker’s inability to salvage a takeover deal with Germany’s Fresenius SE.